Open label study to assess 12 weeks of add-on VTAMA® (tapinarof) Cream, 1% QD in patients with ≥3% BSA who have received biologic therapy for at least 24 weeks.

Inclusion Criteria:

1. Male or female adult ≥ 18 years of age;
2. Diagnosis of chronic plaque-type
3. Patient with ≥3% BSA
4. Patient has been treated with biologic for a minimum of 24 weeks
5. Able and willing to give written informed consent prior to performance of any study-related procedures.

Exclusion Criteria:

1. ≤3% BSA
2. Patient not receiving biologic agent, or receiving biologic agent <24weeks